Loading...
Lexeo Therapeutics, Inc. Common Stock
LXEO•NASDAQ
Healthcare
Biotechnology
$-0.45(-7.00%)
U.S. Market opens in 52h 33mLexeo Therapeutics, Inc. Common Stock (LXEO) AI-Powered Stock Analysis
See how Lexeo Therapeutics, Inc. Common Stock scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerLexeo Therapeutics, Inc. Common Stock (LXEO) Stock Overall Grade
Lexeo Therapeutics, Inc. Common Stock’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Lexeo Therapeutics, Inc. Common Stock's overall stock rating.
Forecast
B+Score
70/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
56/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
B+Score
78/100Lexeo Therapeutics, Inc. Common Stock (LXEO) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 70/100 (B+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (56/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), it shows competitive strength. Analyst Consensus (78/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Lexeo Therapeutics, Inc. Common Stock stock grade, including financials, comparisons, and forecasts.